98%
921
2 minutes
20
"MiRNA-218 regulates osteoclast differentiation and inflammation response in periodontitis rats through MMP9", Cell. Microbiol. 2019;21:e12979, by Jie Guo, Xuemin Zeng, Jie Miao, Chunpeng Liu, Fulan Wei, Dongxu Liu, Zhong Zheng, Kang Ting, Chunling Wang, and Yi Liu. The Editors of Cellular Microbiology and the publisher John Wiley & Sons agree to publish an Expression of Concern regarding the above article, published online in Cellular Microbiology on November 16, 2018, in Wiley Online Library (https://onlinelibrary.wiley.com/doi/full/10.1111/cmi.12979). In September 2019, the journal was contacted regarding concerns about the data presented in Figures 6 and 7 because of high level of similarities in the graphs presented in these figures. The different bars in the graphs show identical height. The standard deviation bars are also of identical length. Although one graph expresses the number of TRAP-positive cells (Figure 6b) and the other graphs express the relative mRNA expression of different osteoclast-related genes (Figure 6c-g), all graphs are identical. The bars in the graphs in Figure 7 that represent 5 different osteoclast genes show the same height. Figures 6 and 7 show identical mRNA expression for a series of different genes: V-ATPase, NFATc1, CTSK, DC-STAMP and TRAP. In December 2019, the journal requested the authors to provide the raw data of the experiments presented in the article and for explanations of the similarities. The authors responded that the similarities were due to unintentional errors and provided Excel spread sheets containing processed data in March 2020. The data provided in the Excel sheets that were sent by the authors were analyzed and it was concluded that the calculations as shown in the Excel sheets are correct. However, the concerns raised regarding similarities in the heights of bars representing different parameters and narrow range of standard deviations presented in Figures 6-7 remained. The authors disagree with the concerns raised. In addition, the editors were concerned by manipulations of western blot images to represent single bands instead of doublets for COL1 in Figures 5 and 8 and for MMP9 in Figures 3A and C, 4C, 5A and D, and 8A. The first issue concerning COL1 bands has been addressed and corrected during the peer-review process. The latter has been clarified after publication and following a request from the editors for the raw data of all figures in the article. In the published article, western blots of MMP-9 in Figures 3A and C, 4C, 5A and D, and 8A show active-MMP-9 only and do not include pro-MMP-9 bands that were present in the original western blot experiments. The authors explained that on the original blots that were provided during the peer-review process, MMP-9 show doublets that represent pro-MMP-9 and active-MMP-9. As no significant difference was found for pro-MMP-9, the authors only presented single bands for active-MMP-9 in the publication version. The authors' institution, Shandong University, did not respond to a request from the Publisher and the Editor-in-Chief to investigate whether the data arose from the originally reported experiments, are unmodified, and are suitable for publication. As a result, the journal is issuing this expression of concern to readers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/cmi.13259 | DOI Listing |
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Dept. of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
The purpose of this study was to investigate the efficacy and safety of add-on metformin treatment in persons with active epilepsy (a-PWE). This is a single-centric, double-blind, placebo-controlled trial randomised a-PWE (1:1) to receive either metformin (extended-release 500 mg) or matching placebo for 6 months along with background antiseizure medications. Primary outcome was percentage change in seizure frequency/month, and secondary outcomes were 50% responder rate, serum mTOR expression, and serum total antioxidant capacity (TAC), body composition analysis, quality of life (QOL), and safety assessment.
View Article and Find Full Text PDFRadiat Environ Biophys
September 2025
Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Sodium orthovanadate (vanadate), a potent inhibitor of p53, has been shown in earlier work to alleviate total-body irradiation (TBI)-induced hematopoietic syndrome. However, as p53 plays a crucial role in normal spermatogenesis, its suppression may raise concerns about potential adverse effects on male reproductive function. In this study, we investigated whether vanadate exacerbates impairment of male fertility when administered for hematopoietic protection under TBI conditions.
View Article and Find Full Text PDFJ Physician Assist Educ
September 2025
Andrew P. Chastain, DMS, PA-C, is an assistant professor at Butler University, Indianapolis, Indiana.
Introduction: Artificial intelligence tools show promise in supplementing traditional physician assistant education, particularly in developing clinical reasoning skills. However, limited research exists on custom Generative Pretrained Transformer (GPT) applications in physician assistant (PA) education. This study evaluated student experiences and perceptions of a custom GPT-based clinical reasoning tool.
View Article and Find Full Text PDFAnn Surg
September 2025
Department of Surgery, University of Wisconsin-Madison.
Objective: We evaluated the empirical fit of our model of clinical momentum for older adults with life-limiting illness undergoing unplanned surgery.
Background: Older adults often undergo surgery near the end of life, in contrast to generally stated preferences. Systems forces promoting intervention may produce nonbeneficial treatment despite advances in communication.
Mol Ther Methods Clin Dev
June 2025
Université Paris-Saclay, University Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France.
Pompe disease is a glycogen storage disorder caused by mutations in the acid α-glucosidase (GAA) gene, leading to reduced GAA activity and glycogen accumulation in heart and skeletal muscles. Enzyme replacement therapy with recombinant GAA, the standard of care for Pompe disease, is limited by poor skeletal muscle distribution and immune responses after repeated administrations. The expression of GAA in muscle with adeno-associated virus (AAV) vectors has shown limitations, mainly the low targeting efficiency and immune responses to the transgene.
View Article and Find Full Text PDF